tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Passage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
PremiumRatingsPassage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
2M ago
Passage Bio Highlights PBFT02 Progress and Extended Cash Runway
Premium
Company Announcements
Passage Bio Highlights PBFT02 Progress and Extended Cash Runway
2M ago
Two new option listings and eighteen option delistings on December 22nd
Premium
The Fly
Two new option listings and eighteen option delistings on December 22nd
3M ago
Passage Bio Reports Q3 Financial Results and Updates
PremiumCompany AnnouncementsPassage Bio Reports Q3 Financial Results and Updates
4M ago
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
Premium
The Fly
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
4M ago
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
Premium
Company Announcements
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
5M ago
Passage Bio Reports Promising Q2 2025 Financial Results
PremiumCompany AnnouncementsPassage Bio Reports Promising Q2 2025 Financial Results
7M ago
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
Premium
The Fly
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
7M ago
Passage Bio expects cash to fund operations into Q1 of 2027
Premium
The Fly
Passage Bio expects cash to fund operations into Q1 of 2027
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100